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Objective: The ideal substitute for the treatment of ventricle–pulmonary
artery discontinuity remains a topic of controversy, because of calcifica-
tions and degeneration of biologic substitutes leading to subsequent
reoperations. Because polyurethane valves used in ventricular assist de-
vices show a satisfactory biocompatibility, the aim of this study was to
evaluate a valved conduit composed of a Dacron graft incorporating a
trileaflet 25 mm polyurethane valve. Methods: The conduit was implanted
between the right ventricle and the main pulmonary artery in adult sheep,
with ligation of the proximal pulmonary artery. The animals received no
medications. Serial hemodynamic data were collected at the time of
implantation and at postoperative intervals of 6 and 12 months. Results:
The peak pressure gradient across the valve increased significantly between
implantation (0.17 6 5.6 mm Hg) and 6 months after operation (7.3 6 3
mm Hg, p 5 0.0007) and remained stable thereafter (6.7 6 3 mm Hg at 12
months), whereas the cardiac output remained unchanged (4.6 6 0.6 L/min
at implantation, 4 6 0.6 L/min at 6 months, and 3.9 6 1.1 L/min at 12
months). At the completion of the study, valve samples were processed and
vapor coated with carbon for microscopic examination. There was one
instance of nonadherent thrombus formation inside a cusp but no struc-
tural failures. The other valves were free of calcium deposits and no
significant amounts of phosphorus could be detected by scanning electron
microscopy and energy dispersive spectrometry. Conclusions: These data
demonstrate the good hemodynamic performance, low thrombogenicity,
and acceptable durability of the polyurethane valves implanted in the right
side of the heart in a chronic sheep model. (J Thorac Cardiovasc Surg 1998;
115:898-903)
Right ventricle–pulmonary artery (RV-PA) an-atomic discontinuity is present in approxi-
mately 5% of hearts with congenital defects.1 In
such cases, the surgical treatment may require the
use of an RV-PA conduit. Different substitutes
have been proposed including fresh aortic ho-
mografts,2 Dacron valved conduits containing bio-
prostheses3-6 or mechanical valves,7 and more
recently cryopreserved aortic or pulmonary ho-
mografts.8-11 Whichever kind of substitute is used,
many studies report valvular calcifications or de-
generation associated with pseudointimal prolif-
eration and progressive obstruction of the con-
duit,4, 8, 9, 11, 12 imposing later reoperations with a
rate ranging from 14% to 30% at 5 years and 32%
to 100% at 10 years.4, 5, 10-13
During the past decade we have observed an
excellent immediate biocompatibility of the polyure-
thane valves used in temporary ventricular assist
devices.14 Although the follow-up in this specific
group of patients is rather short, low rates of
thromboembolic complications and no valvular fail-
ures or calcifications have been reported. Such
valves have been implanted experimentally with
satisfactory results in long-term left ventricular as-
sist devices between the apex of the left ventricle
and the aorta.15 Furthermore, this valvular substi-
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tute will be used in one of the next generation of
total implantable artificial hearts.16
However, the midterm outcome of such artificial
valves has not been documented in the right side of
the heart exposed to both low pressures and oxygen
saturation levels. The aim of this experimental study
was to evaluate the midterm hemodynamic perfor-
mance, calcification occurrence, and durability of a
new type of polyurethane valved conduit implanted
as the only route between the RV and the PA in the
fully mature sheep model for a 1-year period.
Methods
Conduit prototype (Fig. 1). The conduit consists of a
trileaflet polyurethane valve (Abiomed Inc., Danvers,
Mass.) assembled with a low-porosity Dacron graft, 25
mm in diameter (no. 244422, Boston Scientific Corp.,
Natick, Mass.). The three cusps are heat sealed within a
polyurethane housing. An outside stent maintains some
rigidity and avoids external compression of the soft poly-
urethane chamber. Each extremity is heat sealed to the
Dacron conduit. The transvalvular gradient was tested in
vitro at the time of manufacture, and for the set of valves
implanted the mean value was 8 6 1.2 mm Hg for a mean
flow rate of 8 L/min (peak flow 18 L/min).
Experimental protocol. The conduit was implanted in 6
adult sheep (weight 50 6 3.6 kg). All animals received
humane care in compliance with the guide of the National
Veterinary School for laboratory animal studies. Animals
were anesthetized via a jugular intravenous injection of
ketamine (5 mg/kg) and diazepam (0.25 mg/kg) as a bolus.
The sheep were endotracheally intubated and then sup-
ported by a volume-cycled respirator (MMS 107 ventilator
MMS, 77500, Chelles, France) with a 10 cycle/min respi-
ratory rate and a 15 ml/kg– tidal volume, so as to keep the
arterial oxygen saturation value at 99%. Anesthesia was
maintained with a mixture of 1% to 1.5% inspired halo-
thane and 20% nitrous oxide.
Animals were monitored with three-lead electrocardi-
ography. The left carotid artery was used for systemic
arterial blood pressure monitoring and for blood gas
sampling (Radiometer ABL 330 gas analyzer, Copenha-
gen, Denmark). A 5F PA catheter (Baxter Catheter,
Edwards Critical Care Division, Irvine, Calif.) was intro-
duced percutaneously into the right jugular vein for
complete catheterization of the right side of the heart and
fluid infusion. Pressures were continuously recorded on a
multichannel recorder (type 506 A, Kone Corporation
Instrument Division, Espoo, Finland) with the use of
pressure transducers (PVB transducer, SIMS Smiths In-
dustries, Kirchseeon, Germany).
Technique of implantation. Under sterile conditions, a
left anterior thoracotomy was performed in the fourth
intercostal space. The pericardium was opened anterior to
the phrenic nerve and the heart suspended. The anterior
aspect of the RV was exposed along with the main PA,
which was dissected out and controlled with a tape for
later ligation. The operation was performed without by-
pass and with the use of general anticoagulation (heparin
1 mg/kg) to limit the risk of thrombosis during RV and PA
clamping. The RV anterior wall was clamped laterally
after injection of a bolus of intravenous lidocaine (100
mg) to avoid ventricular rhythm disturbances during the
RV mobilization. An adequate ventriculotomy was per-
formed on the clamped portion. The proximal anastomo-
sis between the RV and the Dacron graft was done with a
running suture of monofilament 4-0 polypropylene. The
end-to-side distal anastomosis was then performed be-
tween the beveled Dacron graft and the main PA laterally
clamped with use of the same suture technique. The
conduit was carefully deaired before the completion of the
anastomosis. Finally, the main PA was ligated proximal to
this anastomosis. The conduit length and positioning were
given paramount attention to avoid any kinking or com-
pression of the conduit or the heart itself by the thoracic
wall (Fig. 2). The operation was completed with chest
closure over a chest tube left in place for 4 hours after
extubation of the animal. An antibiotic was prescribed for
5 days. No cardiac medications were given and particularly
no anticoagulation therapy. The animals were left fully
ambulatory for the remainder of the study.
Data acquisition. Hemodynamic data were collected at
the time of operation (T0) and at 6 (T1) and 12 (T2)
months after operation. These data consisted of complete
Fig. 1. Polyurethane valved conduit heat sealed to the
Dacron graft. Fig. 2. Operative view of the RV-PA conduit implanted
into position.
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pressure values in the right side of the heart including RV
systolic pressure, RV end-diastolic pressure; systolic, dia-
stolic, and mean PA pressure; PA occluded pressure; and
pressure gradient along the right side of the heart. Cardiac
output was also measured. All pressure measurements
were obtained under conditions similar to the preimplan-
tation conditions, that is, with the animals placed under
general anesthesia and with use of a Swan-Ganz catheter
(Baxter) introduced into the right jugular vein.
Pathologic examination was performed at the end of the
study after the sheep were electively killed. The heart-lung
blocks and prosthetic materials were removed. A macro-
scopic study was initially done to search for calcifications,
thrombosis, and pseudointimal proliferation. A micro-
scopic study was secondarily performed. The valves were
stored in formaldehyde baths. They were rinsed with
ethanol and cut on a band saw into several pieces.
Segments of leaflets from each valve that included a valve
edge and a piece of the commissures were rinsed again in
ethanol after cutting, then dried at 40° C in air. The
samples were vapor coated with carbon and examined by
scanning electron microscopy (SEM) and energy disper-
sive spectrometry (EDS) methods (Analytical Answers,
Woburn, Mass.). Only the proximal or inflow side of each
valve was examined by microscopy because this is the most
likely site for calcifications to occur.
Statistical analysis. Results were expressed as mean
plus or minus the standard deviation. The Wilcoxon t test
and repeated-measures analysis of variance were used to
compare changes in hemodynamic parameters at each
time.
Results
The animals had a “normal life” after operation
without clinical manifestations of infection, emboli,
or other conduit-related complications.
Analysis of the hemodynamic data collected at the
three different times (Table I) revealed only two
variables with statistically significant changes. The
RV end-diastolic pressure remained stable between
T0 and T1, but decreased significantly between T1
and T2. A significant increase in the pressure gradi-
ent at the valve level appeared between T0 and T1,
and the pressure remained stable thereafter. Given
the length of the conduit, the pull-back pressure
curve could easily rule out pressure gradients at
either the proximal or distal anastomosis. Unlike the
pressure gradient, the cardiac output remained sta-
ble over time (Table I).
At macroscopic study, there was no significant
ventricular hypertrophy. There were no instances of
pulmonary emboli or infectious endocarditis found
by thorough macroscopic dissection of the pulmo-
nary vascular bed at autopsy. A pseudointimal pro-
liferation was usually observed inside the Dacron
grafts, but the polyurethane chambers seemed free
of macroscopic deposits. The valves appeared visu-
ally to be smooth surfaced. No structural valve
deterioration (fracture, leaflet tear, or macroscopic
calcification) was observed. There was one instance
of valve thrombosis partially molding the distal side
of one cusp and not strongly adherent to the valve
surface. The details of each explant analysis are as
follows.
Valve 1. This was the valve partially blocked by
tissue deposits. SEM of the polymer surface of the
valve leaflet showed very thin, patchy deposits, some
of which contained calcium (the others were mainly
sodium chloride). The calcium deposits were pre-
dominantly found along the edge of the leaflets. The
morphologic features of the calcium-containing de-
posits were not similar to those on the other valves;
these deposits were flatter and less crystalline in
appearance. Overall, the leaflet surface was rela-
tively clean but there were some adhering proteins
near the commissure and scattered salt (NaCl)
crystals all over the leaflet.
Valve 2. This valve was mostly clear. SEM
showed some small calcium-containing deposits
about 10 to 20 mm in size, which were more preva-
lent near the tip of the leaflet than near the base.
The largest deposits were about 100 mm in size.
Valve 3. SEM showed a very clean surface with
small scattered nodules of a few microns in diame-
ter, which EDS determined to be of a very high
Table I. Hemodynamic data at each data collection point
Hemodynamic parameter T0 T1 T2
RV systolic pressure (mm Hg) 26.00 6 5.66 27.00 6 6.00 32.33 6 7.53
RV end-diastolic pressure (mm Hg) 11.67 6 6.22 11.33 6 3.67 3.50 6 1.81*
PA systolic pressure (mm Hg) 26.17 6 5.12 19.67 6 6.74 25.83 6 8.45
PA mean pressure (mm Hg) 18.17 6 5.60 13.00 6 5.02 17.83 6 4.45
PA diastolic pressure (mm Hg) 12.67 6 7.20 8.33 6 3.27 10.83 6 4.58
PA occluded pressure (mm Hg) 13.00 6 6.13 12.00 6 4.55 14.50 6 6.53
RV-PA systolic gradient 0.17 6 5.60 7.33 6 3.01† 6.70 6 3.00†
Cardiac output (L/min) 4.60 6 0.60 4.00 6 0.60 3.90 6 1.10
*p 5 0.001 between T0 and T2 and p 5 0.01 between T1 and T2 (analysis of variance).
†p 5 0.007 between T0 and T1 and p 5 0.04 between T0 and T2.
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calcium content. Image analysis estimated surface
coverage by the nodules of 3% to 4%.
Valve 4. This valve was very clear and clean with
no visible deposits. SEM showed a fairly uniform
distribution of very small calcium nodules, less than
1 mm in diameter (Fig. 3). There were more nodules
per unit area than in valve 3, but they were much
smaller. EDS confirmed the high calcium content of
the nodules (Fig. 4). Surface coverage determined
by image analysis was 6% to 9%.
Valve 5. SEM showed a mostly clear surface with
a fairly even distribution of very small nodules (1
mm). The EDS spectrum of the nodule showed a
very high calcium content. Surface coverage by
nodules was 3% to 5% as determined by image
analysis.
Valve 6. This valve had very dark coloration on
the leaflets. SEM showed very light, minor deposits.
One feature near the base of the leaflet was a small
piece of material, 10 to 100 mm in size, approxi-
mately, which had been partially encapsulated in
calcium-containing deposits. This feature was
unique and not a uniform feature of the surface.
Globally, the valves were relatively free of depos-
its and particularly free of calcified deposits. The
only apparently remarkable finding in the analysis
was the almost complete absence of phosphorus
when calcium was present. The calcium-containing
deposits were not hydroxyapatite, but another form
of calcium compound with a very high net calcium
content. No deposits containing significant amounts
of phosphorus could be found on any of the valves.
Discussion
To the best of our knowledge, chronic (1 year)
animal implantation of polyurethane valves has
never been reported in the right side of the heart
exposed to low pressures and oxygen saturation
levels. Such an experimental study addresses three
issues, namely prototype specifications, calcification
of the material, and midterm hemodynamic perfor-
mance of the device.
Prototype specifications. The softness of the
polyurethane housing presents a potential risk of
compression or kinking, which was not observed in
this study, because the metal stent maintains some
rigidity. However, there still remains some risk of
pseudointimal proliferation or calcification within
the Dacron fabric part of the conduit, but this
should be minimized in reducing the Dacron fabric
length and the blood-contacting surface exposed to
this material. Heat sealing between polyurethane
and other material such as polytetrafluoroethylene
would represent an alternative to prevent pseudo-
intimal proliferation, at the expense of a more
demanding manufacturing process. Moreover, no
fibrous deposits were observed on the polyurethane
component of the conduit. Thus it would be inter-
esting to coat the inner part of the Dacron tube with
polyurethane and to evaluate the long-term out-
come of such material. Furthermore, the conduit
was implanted in fully grown sheep and its diameter
(25 mm) was larger than that of homografts or
bioprostheses routinely used in children, particularly
in cases of primary repair of RV-PA discontinuity.
Future studies are mandatory to evaluate smaller-
sized conduits exposed to a more important risk of
compression in an infant chest.
Calcification. The three main hypotheses raised
by calcium deposition on valvular substitutes are
mechanical, biochemical, and time exposure.
There is no clear-cut relation between mechanical
stress failure and calcification occurrence. In vitro
studies reported calcifications on polyurethane
valves after fatigue testing in a systemic loop17 and
roentgenographic analysis indicated that calcifica-
tions were specifically associated with the areas of
failure.18, 19 Thus calcifications should be related to
the stress failure observed in a high-pressure system.
In vivo, polyurethane mitral valves implanted in
juvenile sheep and explanted after 20 weeks were
found to be free of failure but presented macro-
scopic calcified nodules on the outflow surface of
the valve and large calcific plaquelike deposits on
Fig. 3. Photomicrograph of a valve explanted at 1 year,
showing a mostly clear surface with a fairly even distribu-
tion of 1 mm size nodules.
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the inflow surface.18 Similarly, polyurethane valved
apicoaortic conduits implanted in calves revealed
calcifications without polyurethane failure after 4 to
5 months of follow-up.15 In our study, no surface
failures were observed on the polyurethane. This
may be, in part, because the valves were implanted
in a low-pressure cavity.
Calcifications could be related to alterations in
the chemical properties of the polyurethane,17 be-
cause various low molecular weight components
extracted from polyurethane are known to form
polymer-calcium complexes.17, 18 Preimplantation
exposure to bioactive agents such as antioxidants or
surfactants is effective in reducing the calcifications
of polyurethane valves.18, 20, 21 However, adsorbed
plasma phospholipids and proteins containing car-
boxylated amino acids may be potential initiators of
mineralization of such valves.18
The relation between time exposure and calcifi-
cation occurrence is not clear. In vivo, calcium
deposits have been reported on polyurethane valves
in the mitral position after 30 days in the sheep18
and on artificial heart polyurethane diaphragms
after 62 days in the calf.22 However, some devices
remained free of calcium deposits after 120 days15
or 250 days23 of observation. In our study the rate of
calcification was low within a midterm follow-up (1
year) although the sheep can be considered as an
accelerated model of mineralization.18, 20
Hemodynamic performance. In vivo, early steno-
sis was reported after polyurethane mitral valve
implantations in sheep.18 The mean pressure gradi-
ents increased from 9.0 6 2.2 mm Hg at the time of
implantation to 17.9 6 5.0 mm Hg at the end of the
study (20 weeks later), but the cardiac output de-
creased significantly during the same period. In our
study, the gradient remained stable over a longer
follow-up period without a significant difference in
cardiac output. The importance of the gradient
could be related to the thickness of the polyure-
thane24; the compound used in our study was 0.3
mm thick compared with a 0.28 mm thickness used
in the mitral position in another study.18
The closing regurgitation (reverse flow during
valve closure) and leakage (reverse flow through the
closed valve) within the trileaflet polyurethane
Fig. 4. EDS spectrum of a nodule showing a high calcium content.
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valves is less important than that in most mechanical
or biologic valves.24 In our study, in the absence of
an elevated peak systolic RV-PA gradient, low
end-diastolic RV pressure suggested a minimal val-
vular regurgitation. To improve the evaluation of
pulmonary insufficiency, a transthoracic Doppler
echocardiographic study was simultaneously per-
formed. However, in the sheep model, the thorax
anatomy does not provide a valid RV echographic
window, particularly in the postoperative period,
because of pleural adhesions that are in the way of
ultrasonic waves. Moreover, transesophageal echo-
cardiography was not available. The significant drop
observed in RV end-diastolic pressure would sug-
gest a concordant improvement in RV function
which, in the absence of hypovolemia, anemia, or
any related state could not be further assessed in
this specific experimental setting.
Finally, to address the question of durability,
polyurethane valves tested in vitro have demon-
strated a lifetime in excess of 130 millions cycles in
real time and 420 million cycles under accelerated
conditions without polyurethane failure.15 In vivo,
the longest implant of a similar substitute within an
artificial heart was 399 days and was terminated
electively because of excessive animal growth.15
In summary, these data demonstrate the good he-
modynamic performance of polyurethane valved con-
duits implanted in the right side of the heart and
particularly the absence of a significant pressure gra-
dient after 1 year of implantation. This study confirms
the good biocompatibility of polyurethane (low throm-
bogenicity in animals without anticoagulant therapy)
and the short-term durability of such composite con-
duits in an accelerated model of mineralization.
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